Lifeboat Foundation

SGLT2 inhibitors, a promising class of diabetes drugs, were shown to significantly lower the rates of heart failure and death in the large CVD-REAL study.

Summary: A team of scientists at Tongji University just announced a breakthrough in regenerating human lungs using stem cells, improving lung function in patients. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

A team of researchers from Tongji University in China announced what they say is a breakthrough in treating lung diseases by regenerating tissue using stem cell transplantation.

In a pilot clinical trial, the treatment proved effective at repairing the lung tissue of two patients suffering from lung diseases, who showed improvements in both symptoms and on CT scans, say the researchers. Zuo Wei is a Tongji University professor who led the research team and says.

Continue reading “Researchers report breakthrough in human lung regeneration” »

Summary: A research team at UCSD discovered a key enzyme that plays a role in burning calories during both obesity and dieting and sabotages weight loss. Moreover, these scientists may have just found an existing drug that counteracts this enzyme. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

Ever wonder why dieting often leads to a plateau in weight loss? It happens because the body is trying to maintain a steady weight by regulating the expenditure of energy. How this happens has remained a mystery until now.

In a paper published on February 8 in the journal Cell, a team of researchers at the University of California San Diego (UCSD) School of Medicine led by Alan Saltiel, Ph.D. has identified a key enzyme that sabotages weight loss efforts during dieting. Dr. Saltiel is the director of UCSD’s Institute for Diabetes and Metabolic Health, and says.

Continue reading “Researchers discover key enzyme sabotaging our weight loss” »

The AHA names evolocumab — a new PCSK9 inhibitor — as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8, 2018. However, this novel cholesterol-lowering drug carries a big price tag.

Summary: The AHA names the PCSK9 inhibitor evolocumab as one of the top 10 heart disease and stroke advances of 2017 in its annual list published on February 8. However, this novel cholesterol-lowering drug carries a big price tag. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

The AHA named the cholesterol-lowering drug evolocumab in its annual top 10 lists of major advances in heart disease and stroke research, published on February 8. Evolocumab belongs to a class of cholesterol-lowering drugs called PCSK9 inhibitors and is injectable drug marketed by Amgen under the brand name Repatha. The two-year FOURIER study reported that evolocumab reduced high cholesterol levels and had few adverse effects.

Continue reading “AHA names PCSK9 inhibitor evolocumab as a top advance in heart disease” »

In a first for medical science, scientists in the UK have successfully created functioning human kidney tissue that produces urine.

Summary: In a first for medical science, researchers in the UK have successfully created functioning human kidney tissue that produces urine. [This article first appeared on the website LongevityFacts. Author: Brady Hartman. ]

In a first for medical science, researchers have successfully created human kidney tissue within a living organism which can produce urine.

Continue reading “Researchers create functioning kidney tissue” »

Researchers just reported promising rapamycin clinical trial results in the first of its kind test of the drug’s safety and anti-aging effects on healthy Senior adults. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

A rapamycin clinical trial using healthy adults recently completed and reported the drug to be safe over the short-term when used for anti-aging purposes.

This clinical trial of rapamycin was one of the first testing the compound’s safety as an anti-aging drug in healthy Seniors. The clinical trial consisted of 25 healthy older adults 70–95 years between the ages of 70 to 95. The study participants took either a placebo or 1mg rapamycin daily for eight weeks. The main finding of the study was that the drug was safe, without significant side effects. The researchers published their results on February 3 in the journal Experimental Gerontology and concluded.

Continue reading “Researchers report promising anti-aging rapamycin clinical trial results” »

A Japanese scientist regrows hair follicles at record rate using a special ingredient – this novel technique could revolutionize the treatment of baldness. [This article first appeared on the website LongevityFacts.com. Author: Brady Hartman. ]

While scientists aim to lengthen our lifespans, at least they can lengthen our locks.

Or even grow a full head of hair on a bald pate, in the near future.

A scientist gets to the roots of hair loss in a study published at the end of January, saying baldness is due to metabolic changes and free radical damage – and suggests ways to solve the problem. [This article first appeared on LongevityFacts. Author: Brady Hartman. ]

Why We Grow Bald

Scientists have identified at least nine mechanisms that underly the aging process, the so-called hallmarks of aging. While there are many factors that contribute to baldness, including hormonal changes, two of these hallmarks have been implicated in age-related hair loss in women in a study published in late January of this year.

Display of a candidate event for a W boson decaying into one muon and one neutrino from proton-proton collisions recorded by ATLAS with LHC stable beams at a collision energy of 7 TeV. (Image: CERN In a paper published today in the European Physical Journal C, the ATLAS Collaboration reports the first high-precision measurement at the Large Hadron Collider (LHC) of the mass of the W boson. This is one of two elementary particles that mediate the weak interaction – one of the forces that govern the behaviour of matter in our universe. The reported result gives a value of 80370±19 MeV for th…